Neuroendocrine Carcinoma Clinical Trials

76 clinical trials for Neuroendocrine Carcinoma across international registries, including 18 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity — RECRUITING · PHASE2
• The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] — RECRUITING
• A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. — RECRUITING · PHASE1
• SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) — RECRUITING · PHASE1
• Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) — RECRUITING · PHASE3
• Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma — RECRUITING · PHASE1
• ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma — RECRUITING · PHASE1
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors — RECRUITING · PHASE1
• Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI — RECRUITING · PHASE2
• RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide — RECRUITING
• Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary — RECRUITING · PHASE2
• Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies — RECRUITING · PHASE1
• Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas — RECRUITING · PHASE2
• Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) — RECRUITING
• Clinical Application of the J-PET Scanner Prototype — RECRUITING
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. — RECRUITING · PHASE1
• Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. — RECRUITING · PHASE1
• Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC — RECRUITING
• NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas — COMPLETED · PHASE1
• A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate — NOT_YET_RECRUITING · PHASE1
• RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma — COMPLETED · PHASE2
• Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer — COMPLETED · PHASE1
• Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma — NOT_YET_RECRUITING · PHASE3
• Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas — ACTIVE_NOT_RECRUITING · PHASE2
• Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract — COMPLETED
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) — ACTIVE_NOT_RECRUITING · PHASE1
• Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors — COMPLETED · PHASE2
• Neuroendocrine Tumors - Patient Reported Outcomes — ACTIVE_NOT_RECRUITING
• Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) — COMPLETED · NA
• Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET — TERMINATED · PHASE2
• Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) — COMPLETED · PHASE2
• Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma — COMPLETED · PHASE2
• CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas — TERMINATED · PHASE2
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas — COMPLETED · PHASE1
• Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma — COMPLETED · PHASE2
• An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours — OTHER · PHASE2
• A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 — ACTIVE_NOT_RECRUITING · PHASE2
• Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients — OTHER · PHASE2
• PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC — OTHER
• Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms — COMPLETED · NA
• Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms — OTHER · PHASE2
• Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin — OTHER · PHASE2
• Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma — COMPLETED · PHASE2
• TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors — COMPLETED · PHASE2
• A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors — COMPLETED · PHASE1

Refine this search